CD40 Ligand (CD40L) Antibody Market Report 2026

The cd40 ligand (cd40l) antibody market size has grown rapidly in recent years. It will grow from $0.69 billion in 2025 to $0.76 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to advances in immunology research, increasing autoimmune disease prevalence, growth in biologics development, expansion of research funding, improved antibody engineering.

The cd40 ligand (cd40l) antibody market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growth in immunotherapy pipelines, rising transplant procedures, expansion of targeted immune therapies, increasing clinical trial activity, growing biotech investments. Major trends in the forecast period include growing research in immune modulation therapies, increasing development of monoclonal cd40l antibodies, rising focus on autoimmune and transplant indications, expansion of preclinical and clinical studies, increased collaboration between pharma and research institutes.

The increasing prevalence of autoimmune disorders is anticipated to propel the growth of the CD40 ligand (CD40L) antibody market in the coming years. Autoimmune disorders arise when the immune system mistakenly attacks the body's own cells, leading to conditions such as rheumatoid arthritis, lupus, and type 1 diabetes. The rising occurrence of autoimmune disorders is linked to factors including environmental triggers, genetic susceptibility, lifestyle changes, and improved diagnostic awareness, all of which contribute to higher detection rates and overall prevalence. CD40 Ligand (CD40L) antibodies are gaining attention as a promising therapeutic option for managing autoimmune disorders by regulating the immune system's excessive response. For example, in May 2023, data from the University of Oxford, a UK-based research institution, indicated that autoimmune disorders affect approximately one in ten individuals, with 13% of women and 7% of men affected across 19 analyzed autoimmune conditions. Consequently, the increasing prevalence of autoimmune disorders supports the expansion of the CD40 ligand (CD40L) antibody market.

Major companies operating in the CD40 ligand (CD40L) antibody space are emphasizing the advancement of clinical trials and the broadening of therapeutic applications, including CD40L-targeted immunomodulated xenotransplantation to improve graft survival in genetically modified porcine-to-human heart transplants. CD40L-targeted immunomodulated xenotransplantation involves transferring organs, tissues, or cells between different species while employing therapies that block the CD40 ligand (CD40L) pathway to regulate the recipient’s immune response, minimize organ rejection, and enhance graft survival. For example, in September 2023, Eledon Pharmaceuticals Inc., a US-based biotechnology firm, reported the use of Tegoprubart anti-CD40L antibody in a clinical trial following the second-ever genetically modified pig heart transplant. The trial aimed to evaluate its effectiveness in preventing organ rejection and expanding therapeutic applications in organ transplantation. Tegoprubart has also demonstrated potential in managing autoimmune disorders by modulating immune responses.

In January 2023, eGenesis Inc., a biotechnology company based in the US, formed a partnership with Eledon Pharmaceuticals Inc. Through this collaboration, eGenesis will integrate Eledon’s anti-CD40L antibody, tegoprubart, into its preclinical research aimed at creating human-compatible organs and cells for transplantation. Eledon Pharmaceuticals Inc. is a US-based biotechnology firm focused on developing innovative immunotherapies.

Major companies operating in the cd40 ligand (cd40l) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.

North America was the largest region in the CD40 ligand (CD40L) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cd40 ligand (cd40l) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cd40 ligand (cd40l) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised the cost of biologic inputs, cell culture materials, and laboratory reagents used in CD40L antibody development. The impact is most evident during research and clinical development stages, where access to specialized materials is critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global biologics supply chains. Rising tariff related expenses have influenced research budgets, trial planning, and development timelines. Tariffs have encouraged local sourcing of biologic materials, regional supplier development, and stronger domestic research manufacturing capabilities over the long term.

The cd40 ligand (cd40l) antibody market research report is one of a series of new reports that provides cd40 ligand (cd40l) antibody market statistics, including cd40 ligand (cd40l) antibody industry global market size, regional shares, competitors with a cd40 ligand (cd40l) antibody market share, detailed cd40 ligand (cd40l) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd40 ligand (cd40l) antibody industry. This cd40 ligand (cd40l) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CD40 ligand (CD40L) antibody is a treatment that targets the CD40L protein to inhibit CD40-CD40L interactions, thereby regulating immune responses for use in autoimmune disorders, transplant rejection, and cancer immunotherapy. It influences the immune system by preventing the interaction between CD40L and CD40, which plays a key role in immune activation.

The primary types of CD40 ligand (CD40L) antibodies are monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are derived from a single cell clone and are specifically designed to bind to a particular epitope on an antigen. These antibodies are employed in techniques such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blotting, immunoprecipitation, immunofluorescence, and other related applications. The end-users of these antibodies include hospitals, research institutes, specialty clinics, and a variety of other organizations.

The CD40 ligand (CD40L) antibody market consists of revenues earned by entities by providing services such as custom antibody development, recombinant antibody engineering, antibody purification, and functional assays and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD40 ligand (CD40L) antibody market includes sales of infusion pumps and monoclonal antibody testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.